Soligenix Inc (SNGX)
3.665
-0.04
(-0.95%)
USD |
NASDAQ |
Nov 14, 12:38
Soligenix Research and Development Expense (Quarterly): 0.533M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.533M |
| March 31, 2024 | 1.095M |
| December 31, 2023 | 0.7775M |
| September 30, 2023 | 0.826M |
| June 30, 2023 | 0.7627M |
| March 31, 2023 | 0.9465M |
| December 31, 2022 | 2.358M |
| September 30, 2022 | 1.792M |
| June 30, 2022 | 2.048M |
| March 31, 2022 | 1.747M |
| December 31, 2021 | 2.702M |
| September 30, 2021 | 2.238M |
| June 30, 2021 | 1.937M |
| March 31, 2021 | 1.310M |
| December 31, 2020 | 3.659M |
| September 30, 2020 | 1.266M |
| June 30, 2020 | 2.17M |
| March 31, 2020 | 7.700M |
| December 31, 2019 | 2.359M |
| September 30, 2019 | 2.267M |
| June 30, 2019 | 1.854M |
| March 31, 2019 | 1.643M |
| December 31, 2018 | 2.374M |
| September 30, 2018 | 1.395M |
| June 30, 2018 | 1.170M |
| Date | Value |
|---|---|
| March 31, 2018 | 1.803M |
| December 31, 2017 | 1.900M |
| September 30, 2017 | 0.6057M |
| June 30, 2017 | 1.784M |
| March 31, 2017 | 1.218M |
| December 31, 2016 | 0.8623M |
| September 30, 2016 | 1.177M |
| June 30, 2016 | 0.8278M |
| March 31, 2016 | 1.428M |
| December 31, 2015 | 1.668M |
| September 30, 2015 | 1.259M |
| June 30, 2015 | 1.443M |
| March 31, 2015 | 1.030M |
| December 31, 2014 | 1.754M |
| September 30, 2014 | 1.089M |
| June 30, 2014 | 1.213M |
| March 31, 2014 | 1.031M |
| December 31, 2013 | 0.9575M |
| September 30, 2013 | 1.217M |
| June 30, 2013 | 2.140M |
| March 31, 2013 | 0.7567M |
| December 31, 2012 | 0.8601M |
| September 30, 2012 | 0.3713M |
| June 30, 2012 | 0.501M |
| March 31, 2012 | 0.8768M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.533M
Minimum
Jun 2024
7.700M
Maximum
Mar 2020
2.012M
Average
1.792M
Median
Sep 2022
Research and Development Expense (Quarterly) Benchmarks
| Tonix Pharmaceuticals Holding Corp | 9.698M |
| Lixte Biotechnology Holdings Inc | 0.2107M |
| Shuttle Pharmaceuticals Holdings Inc | 0.6457M |
| NovaBay Pharmaceuticals Inc | 0.009M |
| Palatin Technologies Inc | 4.672M |